Search

Your search keyword '"Braun-Moscovici, Yolanda"' showing total 252 results

Search Constraints

Start Over You searched for: Author "Braun-Moscovici, Yolanda" Remove constraint Author: "Braun-Moscovici, Yolanda"
252 results on '"Braun-Moscovici, Yolanda"'

Search Results

1. Contributors

4. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

5. IgG4-related Breast Disease: Review of the Literature.

9. Hypermobility spectrum disorders and irritable bowel syndrome: A nationwide study of 1.6 million adolescents

11. Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes

12. A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations

14. An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey)

15. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

16. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

17. Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.

20. Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

21. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

22. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

23. LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma

25. sj-pdf-1-jso-10.1177_23971983221138712 – Supplemental material for Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0

26. Predictors of an Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab: A Multicenter Study

29. Digital ulcers predict a worse disease course in patients with systemic sclerosis

30. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study

31. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

33. Contributors

35. Peripheral B cells repress B-cell regeneration in aging through a TNF-α/IGFBP-1/IGF-1 immune-endocrine axis

36. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

40. Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0

47. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

48. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

49. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis

50. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

Catalog

Books, media, physical & digital resources